Can FFR-CT Reduce Unnecessary Testing in Moderate CAD?
A recent study published in REC: Interventional Cardiology (2026) explores whether adding FFR-CT (DEEPVESSEL FFR) to standard CCTA can reduce testing in moderate CAD.
Exploring the Future of Non-Invasive Cardiac Diagnostics: Keya at SCCT Global 2025
Keya Medical’s advanced AI solutions and the application of Deep Learning CT-derived Fractional Flow Reserve analysis in non-invasive cardiac diagnostics. Visit us at SCCT 2025, Booth 14.
Keya Medical Presents FDA-cleared CT FFR product at SCCT Global 2024 | Budapest
Visit Keya Medical’s booth at SCCT Global 2024 in Budapest, January 16-19.
Keya Medical Covers Technology Advancements and AI Integration at SCCT 2023: A Look at Exceptional Collaborations.
In the dynamic landscape of medical innovation, SCCT 2023 served as an exceptional platform for exchanging cutting-edge insights and breakthroughs in cardiovascular technology.
The future of AI-driven, noninvasive CT FFR technology-DeepVessel FFR at 2022 cardiology events in China
Keya Medical US celebrates the achievements of the team in China and their commitment to the commercialization of DEEPVESSEL FFR.
DEEPVESSEL FFR, Keya Medical Deep-Learning Based, Non-Invasive Coronary Artery Functional Assessment Software Device, Receives FDA Clearance.
Seattle, WA– April 1, 2022– Keya Medical announced that DEEPVESSEL FFR (DVFFR), has been cleared by U.S. Food and Drug Administration (FDA).
Recent Comments